SalioGen Therapeutics has launched Gene Coding, a genetic medicine platform, to develop durable, broadly applicable genetic medicines, using its Exact DNA Integration Technology (EDITTM) platform. EDIT is based on the novel mammal-derived genomic engineering tool, for use in potentially curative genetic medicines. SalioGen is focused on developing therapies for more patients with inherited diseases that are beyond what is addressable with current technologies, initially focusing on inherited macular disorders and inherited lipid disorders.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 01/05/22 | $115,000,000 | Series B |
Cystic Fibrosis Foundation D1 Capital Partners EPIQ Capital Group  Fidelity Management & Research Company GordonMD Global Investments PBM Capital Group RD Fund Symbiosis T. Rowe Price Associates | undisclosed |
